Search clinical trials for: Fludarabine (Fludara, Berlex Laboratories)

Total 588 results

Samsung Medical Center

Unknown

Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)

Lymphoma | AML | MDS | CML | ALL

Korea, Republic of
National Cancer Institute (NCI)

Completed

Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

MDS | Immunodeficiency | GATA2

United States
National Cancer Institute (NCI)

Recruiting

Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

DOCK8 Deficiency

United States
University of California, San Francisco
Thrasher Research Fund

Completed

Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)

Sickle Cell Disease | Hemoglobinopathies | Fanconi Anemia | Thalassemia | Hematologic Malignancies | Immunodeficiencies | Nonmalignant Diseases | Genetic Inborn Errors of Metabolism

United States
National Cancer Institute (NCI)

Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

MDS | Immunodeficiency | GATA2

United States
German CLL Study Group

Completed

Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany, Austria
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Allogeneic Transplant in HIV Patients (BMT CTN 0903)

Lymphoma | Leukemia | HIV

United States
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Genzyme, a Sanofi Company

Completed

Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

B-Cell Chronic Lymphocytic Leukemia

Sweden, United States, Croatia, Canada, Ukraine, Austria, Bulgaria, France, Germany, Greece, Italy, Poland, Portugal, Romania, Russian Federation
University of California, San Diego
Jazz Pharmaceuticals

Terminated

Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.

AML | AML, Adult | Acute Myeloid Leukemia, Adult

United States
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

Leukemia, Myelocytic, Acute

United States
Wuhan Union Hospital, China

Recruiting

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Allogeneic Hematopoietic Stem Cell Transplantation | Acute Myeloid Leukemia, Adult | Myelodysplastic Syndrome(MDS)

China
Genzyme, a Sanofi Company

Completed

Fludara (Oral) Phase II Study for Indolent Lymphoma

Lymphoma

Japan
M.D. Anderson Cancer Center
Vion Pharmaceuticals

Completed

Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies

Hematologic Malignancies

United States
Genzyme, a Sanofi Company

Completed

Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL

Non Hodgkin Lymphoma

Italy
Genzyme, a Sanofi Company

Completed

A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia

Leukemia, Lymphocytic, Chronic, B-Cell
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Radiation Therapy Plus Fludarabine in Treating Patients With Locally Advanced Cancer of the Mouth, Pharynx, or Larynx

Head and Neck Cancer

United States
GeoVax, Inc.
Emory University; Stanford University; Thomas Jefferson University

Recruiting

Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

Recurrent Head and Neck Cancer

United States
West Virginia University

Completed

Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

United States
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Terminated

Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders (MASCI)

Severe Combined Immunodeficiency Disease | Severe Primary Immunodeficiency Disorder | Undefined T Cell Deficiency Disorder | Wiskott-Aldrick Syndrome

United States
University of Illinois at Chicago

Completed

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Polycythemia Vera | Multiple Myeloma | Myelofibrosis | Acute Leukemia | Chronic Myelogenous Leukemia | Aplastic Anemia | Myeloproliferative Disorder | Hodgkin's Disease | Malignant Lymphoma | Lymphocytic Leukemia

United States
Genzyme, a Sanofi Company

Completed

Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL

Lymphoma, Low-Grade

Japan
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Terminated

Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML (MPDMDSBMT)

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders

United States
M.D. Anderson Cancer Center

Completed

Busulfan and Fludarabine in Patients With AML and MDS

Leukemia

United States
Dana-Farber Cancer Institute
Janssen Research & Development, LLC

Recruiting

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Multiple Myeloma | Smoldering Multiple Myeloma

United States
M.D. Anderson Cancer Center
Sanofi

Terminated

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia

United States
Genzyme, a Sanofi Company

Completed

Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)

Leukemia, B-Cell, Chronic

Italy
M.D. Anderson Cancer Center

Completed

Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Leukemia | AML | MDS | CML

United States
Celyad Oncology SA

Recruiting

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Belgium, United States
National Cancer Institute (NCI)

Completed

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Philadelphia Chromosome Negative Chronic Myelogenous... and other conditions

United States
M.D. Anderson Cancer Center

Completed

CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)

Leukemia | Advanced Cancers

United States
M.D. Anderson Cancer Center

Withdrawn

Infusion of Allogeneic, 3rd Party CD19-specific T Cells

Lymphoma | Leukemia | Blood And Marrow Transplantation
UNC Lineberger Comprehensive Cancer Center
Bellicum Pharmaceuticals

Not yet recruiting

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Breast Cancer | Triple Negative Breast Cancer | Relapse | Resistant Cancer

United States
Arbeitsgemeinschaft medikamentoese Tumortherapie
Schering-Plough

Completed

A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response

B-cell Chronic Lymphocytic Leukemia

Austria
National Heart, Lung, and Blood Institute (NHLBI)
GlaxoSmithKline; University of Virginia

Completed

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

Small Lymphocytic Lymphoma | CLL (Chronic Lymphocytic Leukemia)

United States
Hackensack Meridian Health

Completed

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma (Flu-Mel-Vel)

Multiple Myeloma

United States
M.D. Anderson Cancer Center
Intrexon Corporation

Terminated

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

Acute Myeloid Leukemia | Hematopoietic/Lymphoid Cancer

United States
M.D. Anderson Cancer Center

Completed

Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support

Hematologic Malignancies

United States
M.D. Anderson Cancer Center

Completed

Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia

Aplastic Anemia

United States
Sanofi

Terminated

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukaemia

United States
M.D. Anderson Cancer Center

Completed

Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide

Lymphoma | Hematologic Diseases | Leukemia | Myeloma

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Bayer

Completed

Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Hackensack Meridian Health

Terminated

PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation (FLUBUTBI)

Myeloproliferative Disorders | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloid Malignancies

United States
Tessa Therapeutics

Active, not recruiting

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

Hodgkin Lymphoma, Adult | Hodgkin Disease Recurrent | Hodgkin Disease Refractory | Hodgkin Disease, Pediatric

United States
UNC Lineberger Comprehensive Cancer Center
Bellicum Pharmaceuticals; University Cancer Research Fund at Lineberger Comprehensive...

Not yet recruiting

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Head and Neck Cancer | Relapse | Refractory Cancer | Recurrent

United States
Randy Windreich

Completed

Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Hematopoietic Stem Cell Transplant (HSCT)

United States
M.D. Anderson Cancer Center

Not yet recruiting

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Hematological Malignancy

United States
Hackensack Meridian Health

Completed

Stem Cell Transplantation for Sickle Cell Anemia

Sickle Cell Disease

United States
M.D. Anderson Cancer Center
Jazz Pharmaceuticals

Withdrawn

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Hematologic Malignancy

Search clinical trials for: Fludarabine (Fludara, Berlex Laboratories)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations